Take­da, CSL Behring fold big plas­ma al­liance af­ter PhI­II flop — join­ing a slew of an­ti­bod­ies that failed to help hos­pi­tal­ized pa­tients

The big plas­ma al­liance spear­head­ed by Take­da and CSL Behring has a big Phase III ver­dict: Adding their hy­per­im­mune in­tra­venous im­munoglob­u­lin prod­uct to Gilead’s remde­sivir …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER